基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:PatchSight-ImmuneMap-LifeSpan as a unified AI framework for breast cancer diagnosis, immune profiling and prognostic prediction.
PatchSight-ImmuneMap-LifeSpan as a unified AI framework for breast cancer diagnosis, immune profiling and prognostic prediction.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
乳腺癌诊断、免疫细胞图谱和生存预测都很重要,但通常分开进行,限制了临床解读。本研究将组织病理学诊断、免疫微环境分析和预后建模整合到一个数据驱动的流程中。所提出的系统包括三个阶段:PatchSight Classifier 使用优化的 InceptionResNetV2 网络,结合基于图像块的增强和迁移学习,从 BreakHis 数据集中对良性和恶性乳腺组织进行分类;ImmuneMap Detector 在 LYSTO 数据集的免疫组织化学图像上使用 Faster R-CNN 检测并量化TIL(肿瘤浸润淋巴细胞);LifeSpan Prognosticator 整合诊断和免疫特征。PatchSight Classifier 在 400× 放大倍数下以 98.76% 的准确率和 0.98 的 F1-score 优于 VGG-16、DenseNet-121 和基线 InceptionResNetV2 模型。ResNet-101 的 ImmuneMap Detector 具有 98% 的检测准确率和较低的淋巴细胞计数误差。LifeSpan Prognosticator 识别出影响生存的生物标志物,C-index 高于 0.90。这一综合计算病理学系统通过可解释的高精度模型提高了诊断精度、免疫评估和生存预测。
我们为早期检测、免疫评估和个性化乳腺癌预后提供端到端决策辅助。
Breast cancer diagnosis, immune cell profile, and survival forecasting are important but usually done separately, limiting clinical interpretation. This work combines histopathological diagnosis, immunological microenvironment analysis, and prognostic modeling into a data-driven pipeline. The proposed system involves three phases: PatchSight Classifier uses an optimized InceptionResNetV2 network with patch-based augmentation and transfer learning to classify benign and malignant breast tissue from the BreakHis dataset; ImmuneMap Detector uses Faster R-CNN on immunohistochemistry images from the LYSTO dataset to detect and quantify tumor-infiltrating lymphocytes; and LifeSpan Prognosticator integrates diagnostic and immune features.
The PatchSight Classifier outperformed VGG-16, DenseNet-121, and baseline InceptionResNetV2 models with 98. 76% accuracy and 0. 98 F1-score at 400× magnification. ResNet-101’s ImmuneMap Detector had 98% detection accuracy and low lymphocyte counting inaccuracy. The LifeSpan Prognosticator identified survival-influencing biomarkers with a C-index above 0. 90. This comprehensive computational pathology system improves diagnostic precision, immunological assessment, and survival prediction with interpretable, high-accuracy models.
We provide end-to-end decision assistance for early detection, immunological assessment, and personalized breast cancer prognosis.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。